Silenor (doxepin hydrochloride) NDC 42847-106

NDC codes

FDA NDC Directory

Product NDC (as listed)42847-106Labeler and product segments. Claims need a package NDC.

Product NDC at billing width42847-0106Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package
42847-106-03	42847010603	30 TABLET in 1 BLISTER PACK (42847-106-03)Marketed from Aug 1, 2010
42847-106-10	42847010610	100 TABLET in 1 BOTTLE (42847-106-10)Marketed from Aug 1, 2010
42847-106-30	42847010630	30 TABLET in 1 BOTTLE (42847-106-30)Marketed from Aug 1, 2010
42847-106-50	42847010650	500 TABLET in 1 BOTTLE (42847-106-50)Marketed from Aug 1, 2010

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Silenor
Generic name (nonproprietary): doxepin hydrochloride
Active ingredients: Doxepin hydrochloride — 6 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Currax Pharmaceuticals LLC
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 022036
Marketing start: Aug 1, 2010
Listing expires: Dec 31, 2027
Identifiers: Product ID 42847-106_cd7bcf13-11a5-4866-9fd0-da073bb3a9a1SPL ID cd7bcf13-11a5-4866-9fd0-da073bb3a9a1SPL set ID 1bec1223-5239-4eb6-a9e8-62444106d2c0RxCUI 966787, 966791, 966793, 966795UNII 3U9A0FE9N5UPC 0342847103309, 0342847106300
Pharmacologic class: Tricyclic Antidepressant

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N442847010603 followed by a unit qualifier and the quantity

Package 42847-0106-03. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Apr 21, 2026.

Indications (excerpt from the label)

1. INDICATIONS AND USAGE SILENOR is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration . SILENOR (doxepin) tablets are indicated for the treatment of insomnia characterized by difficulties with sleep maintenance. ( 1 , 14 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 022036

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 022036
Product	Strength	Form · route	Labeler	Product NDC
doxepin hydrochloride	Doxepin hydrochloride 6 mg/1	TabletOral	Currax Pharmaceuticals LLC dba Cypress, Hawthorn, Macoven	44183-106
doxepin hydrochloride	Doxepin hydrochloride 3 mg/1	TabletOral	Currax Pharmaceuticals LLC dba Cypress, Hawthorn, Macoven	44183-103
Silenordoxepin hydrochloride	Doxepin hydrochloride 3 mg/1	TabletOral	Currax Pharmaceuticals LLC	42847-103